DSG2 and melanoma: Figure 3A shows that patients with DSG2+ stage II melanomas were more likely to develop metastatic disease compared to those with DSG2− tumors (HR = 2.34), but this trend was not statistically significant in this small cohort (p = 0.22 log-rank test; n = 22).